Tremedics
Tremedics develops bioresorbable technology for congenital heart disease patients with congenital heart disease need devices that resorb within their bodies as they grow. Their technology utilises a minimally invasive surgery procedure for stent delivery and permits vessel growth as the stent resorbs in the body.
Industries
health-care
medical-device
Nr. of Employees
small (1-50)
Tremedics
North Richland Hills, Texas, United States, North America
Patents
Products
Illusicor™ Bioresorbable Stents
Polymeric stents designed to be implanted via minimally invasive surgery in children with congenital heart disease, which resorb within the body to allow vessel growth.
Illusicor™ Bioresorbable Stents
Polymeric stents designed to be implanted via minimally invasive surgery in children with congenital heart disease, which resorb within the body to allow vessel growth.